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Background
Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threaten-
ing disorder that occurs due to deficiency of ADAMTS13 (a disintegrin 
and metalloproteinase with a thrombospondin type 1 motif, member 
13), which is a von Willebrand factor (VWF) cleaving protein.[1] 
The absent or severely reduced activity of ADAMTS13 in patients 
with TTP prevents timely cleavage of unusually large multimers of 
VWF as they are secreted by endothelial cells, resulting in adhesion 
and aggregation of platelets in flowing blood, with formation of 
microvascular thrombi, which are responsible for most of the clinical 
features.[2] Both congenital and acquired forms of TTP have been 
described. There are no prevalence or incidence studies on TTP in 
sub-Saharan Africa (SSA), but several case reports are available in 
literature. Scully et al.[3] in the UK reported a TTP incidence rate of 
six cases per million people in 2008. 
There are several causes of acquired TTP, all of which lead to 
decreased activity of ADAMTS13 due to autoantibodies that are 
directed towards ADAMTS13.[4] The classic presentation of TTP 
is that which follows postinfectious intestinal infection with either 
shigatoxin-producing Escherichia coli or Shigella dysenteriae.[5] HIV 
infection has been directly associated with TTP,[6] and a case series 
by Gunther et al.,[7] in South Africa in 2007, demonstrated that HIV-
associated TTP was the most common form of TTP. Postinfectious 
TTP is therefore the most common cause of TTP in SSA, where there 
is still a high incidence of infectious diseases. 
TTP was originally characterised by a pentad of thrombocytopenia, 
microangiopathic haemolytic anaemia, fluctuating neurological deficits, 
renal impairment and fever, often with insidious onset.[8] However, 
TTP can present without the full pentad. Up to 35% of patients do not 
have neurological signs at presentation, and renal abnormalities and 
fever are not always prominent features.[9] Galbusera et al.[9] in 2006 
described revised diagnostic criteria for TTP in which the diagnosis can 
be made upon identification of the presence of thrombocytopenia and 
microangiopathic haemolytic anaemia (MAHA) only. Other atypical 
manifestations of TTP that have been described include non-occlusive 
mesenteric ischaemia, pancreatitis, hepatitis, acute respiratory distress 
syndrome and peripheral digital ischaemia.[10,11]
TTP is a severe illness and, if untreated, >90% of patients die from 
the syndrome.[12] Plasmapheresis is the treatment of choice for TTP, 
in addition to steroids, which are initiated immediately after start of 
plasma exchange therapy (PEX).[8] Rituximab is effective and safe 
in acute idiopathic TTP and in patients with immune TTP who 
have failed to respond to PEX and steroids.[13] The poor outcome of 
untreated patients is a big challenge particularly in SSA, where there 
are poor health systems and poor access to quality healthcare. 
We report a case of a 46-year-old man who presented with most of 
the classic clinical manifestations TTP.
Case presentation
A 46-year-old male patient born deaf and dumb presented to the Aga 
Khan University Hospital as a referral from a peripheral facility, with 
a 2-week history of severe headache, abdominal pains, diarrhoea 
and vomiting. He had been fine prior to the onset of symptoms 
and there was no history of travel to a malaria endemic region. The 
headache was occipital, of sudden onset, severe (scale 8 - 10/10), non-
radiating, worsened with activity and was temporarily relieved by 
use of analgesics. There was no associated fever or neck stiffness. He 
had visual hallucinations with no other visual symptoms. Diarrhoea 
was watery and not blood stained, and the vomiting was mostly 
postprandial with associated epigastric abdominal pain. There was 
no history of decreased urine output, lower-limb swelling and facial 
swelling, and no respiratory symptoms. His past medical history 
and family history were non-significant. He worked as a tailor and 
was married with three children. Physical examination showed a 
well-developed, middle-aged black African male patient of good 
nutritional status and with stable vital signs. He had mild pallor, was 
not jaundiced, had no lymphadenopathy and no oedema, and skin 
examination was normal. He communicated by sign language, his 
neck was supple and the rest of the neurological examination findings 
were unremarkable. Abdominal, respiratory and cardiovascular 
examinations were unremarkable. Laboratory findings showed severe 
anaemia (haemoglobin 5.8 mg/dL), thrombocytopenia (platelet 
counts 9 × 109), increased lactate dehydrogenase activity (517 IU/L) 
and schistocyte count was 3%. Renal and liver function tests were 
normal with a negative direct Coombs test. HIV antibody, hepatitis B 
surface antigen and hepatitis C virus antibody tests were negative. 
Blood and stool cultures were negative, while renal and liver function 
tests were normal; it is important to note that he had been on 
intravenous antibiotics in the referring facility. His blood slide for 
malaria parasites was also negative.
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TTP was suspected because of the haemolytic 
anaemia, thrombocytopenia, schistocytes on 
the peripheral blood film and the neurological 
manifestations. The patient was started on PEX 
at a dose of one volume PEX daily, and the 
efficacy of the plasma exchange was monitored 
using daily thrombocyte levels. Despite being 
on daily PEX, his thrombocytes did not 
improve until after 5 days of therapy. After 
1  week in the hospital, undergoing PEX, he 
was noted to have declining mental status, and 
increased aggressiveness and disorientation. 
Magnetic resonance imaging was not done 
because of the need for sedation. Computed 
tomography scan of the brain showed small 
bilateral subdural haematomas with no pressure 
effects; the patient was put on conservative 
management with continued monitoring of 
neurological status. He improved and there 
was no need for neurosurgical intervention.
After seven sessions of PEX, the thrombo-
cytes improved to 157 × 109/L. PEX was 
stopped after the thrombocyte levels 
remained above 150 × 109/L for 2 consecu-
tive days. Three days after PEX had been 
stopped, the thrombocytes dropped to 47 × 
109/L, and a diagnosis of refractory TTP was 
made. Finan cial constraints limited subse-
quent PEX to one more session, and only one 
dose of rituximab (375 mg/m2 body weight) 
for refractory TTP was given. The throm-
bocytes improved and the patient’s clinical 
condition improved tremendously, and he 
was discharged 4 days after the dose of ritux-
imab. The thrombocyte count improved to 
160   × 109/L on starting rituximab and to 
198 × 109/L on review in a clinic 2 weeks later. 
The patient was discharged on prednisolone, 
tapered over 3 months. He was doing very 
well 3 months post discharge, with no symp-
toms, and he had returned to work. He had a 
platelet count of 253 × 109/L and 233 × 109/L 
on review 2 and 3 months post discharge, 
respectively (Fig. 1).
Discussion
TTP was diagnosed in this patient owing to 
the presence of thrombocytopenia, MAHA 
with schistocytes of 3% and neurological 
manifestations.[9] Systemic bacterial and 
fungal infections were excluded with several 
negative blood cultures, as severe sepsis is 
one of the differentials for schistocytosis and 
thrombocytopenia.[14] Patients with severe 
sepsis may also present with disseminated 
intravascular coagulation with a subsequent 
lack of procoagulant proteins, causing 
bleeding diathesis and anaemia. 
TTP is a life-threatening condition, espe-
cially in SSA, where optimal treatment 
facilities are not available. PEX was initiated 
owing to a presumptive diagnosis of TTP 
because of the associated high mortality of 
up to 90% in untreated patients.[12] PEX is the 
mainstay of treatment in TTP as it reduces 
mortality from 90% to 10 - 20%. [8] This 
moda lity of treatment depletes the circulating 
antibodies against ADAMTS13 and the very 
high molecular weight von Willebrand 
factor multimers. PEX also replaces the 
missing von Willebrand cleav ing protease. [15] 
Although the mortality of TTP has been 
reduced in most European countries and 
in America, we postulate that TTP still has 
a high mortality in SSA owing to lack of 
PEX. Management of refractory TTP is a 
bigger challenge owing to the need for more 
prolonged duration of treatment. However, 
more intensive PEX may be required in 
resis tant cases with new-onset symptoms 
while on therapy.[16] Our patient improved 
tremendously but deteriorated 2  days post-
PEX, with thrombocytes dropping to 47. 
Owing to financial constraints, only one 
additional session of PEX was done for 
refractory TTP and one dose of rituximab 
was given. Fakhouri et al.[13] showed that 
rituximab is effective and safe in immune 
TTP for patients who have failed PEX and 
methylprednisone treatment and in acute 
relapsed TTP. Rituximab is the current 
treatment of choice for refractory TTP and 
should be given once weekly for 4 weeks;[3,8] 
our patient was started on rituximab early 
because of the challenges of PEX in our 
setting. Rituximab in combination with 
predni sone is effective and can be used with-
out concurrent plasma exchange in patients 
without neurological or renal impairment. [17] 
Long-term consequences of TTP are not 
well known, but it has been postulated that 
some patients may go on to develop long-
term renal dysfunction and neurocognitive 
deficits.[15] 
This case report demonstrates both the 
poss ibilities and challenges of managing 
TTP. Diagnosis and initiation of appropriate 
therapy according to international guidelines 
was possible for this patient and a relatively 
good response was demonstrated. However, 
our patient did not receive optimal care 
owing to financial constraints; this is 
a common scenario in SSA. Our patient 
responded well to one dose of rituximab. 
Further studies are necessary to explore the 
viability of use of rituximab alone in settings 
where PEX is not possible.
Conclusions
TTP can present without the full pentad 
of the classic clinical presentation. There 
should be increased suspicion of TTP in 
patients who present with MAHA, especially 
in a population that has a high prevalence 
of HIV infection. This is the first reported 
case of TTP that was relatively appropriately 
managed with plasma exchange and rituxi-
mab in this part of the developing world. 
Rituximab has been used for patients with 
resistant and relapsed TTP with successful 
results in other regions of the world; these 
results can be replicated in our setting. 
Further studies to assess the feasibility 
and viability of the use of rituximab alone 
in settings where PEX is not possible are 
necessary.
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Fig. 1. Platelet counts against intervention. (R = rituximab; wk = weeks; mo = months.)
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